|
|
|
| home > ebr > Spring 2011 |
|
|
 PUBLICATIONS |
European Biopharmaceutical Review |
|
|
|
|
|
 |
| |
|
|
|
|
A Watchful Eye
Michael Rosenberg of Health Decisions Inc explains why monitoring is the single most important safeguard for clinical studies and considers the methods available for accurately gauging the trajectory of a trial.
|
|
|
Digital Directions
As the regulatory pressure on small and medium-sized companies increases, electronic document management system software is being tailored to maintain efficiency standards. Keith Williams of GxPi looks at how to implement these hosted systems to enhance functionality.
|
|
|
Blockbuster Takeover
The acquisition of Genzyme grabbed headlines as the largest pharmaceutical company takeover in the industry for years. Daniel Bastide from Thomas Eggar LLP reports on the negotiations that made the purchase possible.
|
|
|
Perfect Partnering
Ross McLennan of TMRI Ltd shows how a multitude of collaborations between industries can allow for stronger adaptive clinical designs, and details some of the initiates already in place that prove what they can offer.
|
|
|
Software Solutions
The burden of the industry’s livelihood is dependent on the success of partnerships. Alison Shurell at IntraLinks explains how embracing new technology can effectively speed up the communication chain.
|
|
|
|
Standing at the Threshold
Contemplating revisions to the blockbuster ‘one-size-fits-all’ business model, Private Consultant Emile Bellott highlights the reasons why applying genetic-aware therapeutic strategies presents a compelling opportunity for the major industry players.
|
|
|
Accelerating Innovative Vaccines
Scott Preiss, Alberta Di Pasquale, Marleen Mergaerts and Nathalie Garçon at GlaxoSmithKline Biologics discuss vaccines in common use and the factors that go into narrowing down their design goals.
|
|
|
Learning from Experience
Using examples of exogenous virus contamination, Andy Bailey of ViruSure GmbH reviews the vulnerability of the biotech manufacturing process from sources yet to be identified.
|
|
|
Mind the Messenger
Raymond Verhaert and Victor Schut of ProteoNic review the technology affecting translational activity, with specific focus on their application to the study of mammalian and yeast cell culture.
|
|
|
|
|
Stem Cell Innovation
Vanessa Ott and Blake Anson of Cellular Dynamics International look at how the world of induced pluripotent stem cells has changed since it was discovered that they could be extended to human cells.
|
|
|
Big Ideas on a Small Scale
The successful development of miniaturised, automated, speedy and reliable assays in the future will be heavily dependent on nanotechnology, suggests Mike Fisher at NanoKTN in this portrait of what is available currently.
|
|
|
|
Best Practices
Nathalie A Compagnone of Innovative Concepts in Drug Development examines the role of regulatory agencies in diagnostic testing and biomarker development.
|
|
|
New Horizons
Focusing on the rise of the ‘omics’ field, Gustavo Salem of Agilent Technologies, Inc considers the future of integrated biology and explains how a deeper understanding of cellular processes is set to alter the way we view therapeutics.
|
|
|
|
From Lab to Clinic
When streamlining a business, often one of the strongest ways to ensure you have all the necessary expertise is to outsource. Angela Scott and Susan McKee of Angel Biotechnology evaluate the risks and benefits of biomanufacturing using external contractors.
|
|
|
The Perfect Host
John Liddell and Ian Hodgson of MSD BioManufacturing Network demonstrate that if molecule expression can be achieved in E Coli, then lower costs and a faster speed to market will usually follow.
|
|
|
Sustainable Standards
Yaniv Vardi at Sparta Systems Europe Ltd assesses how crucial the enterprise-wide quality management system is in the pharmaceutical and biotechnology industries.
|
|
|
|
Dragon’s Den
In a comparison of the biotech industry’s US and Chinese workforces, Erik Lundh of J. Robert Scott draws on recent survey findings to report on top hiring issues and the international effect of the ‘brain drain’.
|
|
|
|
|
|
 |
|
|
 |
News and Press Releases |
 |
Wool packaging firm’s green scheme goes ‘beyond recycling’
An award-winning company that has spent more than 10 years innovating in
sustainable packaging has launched a scheme that it says goes ‘beyond
recycling’ – by allowing the end user to return their packaging directly
to them to be used again.
More info >> |
|
 |
White Papers |
 |
|
Another Successful Visit Against the Odds
Medical Research Network (MRN) Limited
Our dedicated team of nurses, couriers and project managers deliver, come rain or shine.
Making sure a Clinical Trial visit can go ahead in the home can be a
complex process, and last month bad weather nearly stopped play on an
important Home Trial Support visit. Thanks to the commitment and
dedication from the entire team it went ahead against the odds.
More info >> |
|
 |
Industry Events |
 |
BioPharm America™ 2019—12th Annual International Partnering Conference
11-12 September 2019, Boston Convention and Exhibition Center (BCEC), Boston, MA 02210 USA
BioPharm America™ is a unique partnering event that forms the nexus of discovery and
realization. Startup companies, established biotech and entrepreneurs from academia
attend in search of finance, pharma and development partners. The event format highlights
innovation and promotes new business relationships by bringing dealmakers from the life
science ecosystem together to engage and de-risk the enormous task of drug development.
Life science executives from around the world gather to identify, meet and to enter
into strategic relationships facilitated by partneringONE®, the world’s leading
web-based partnering system. BioPharm America is the only event in North America
based on the same reputable formula as EBD Group’s acclaimed European events
BIO-Europe® and BIO-Europe Spring®. BioPharm America annually attracts 800+ delegates
from over 500 companies who participated in 2,300+ scheduled one-to-one meetings.
BioPharm America is now part of Biotech Week Boston, and together they draw a total
of over 4,500 life science leaders, scientists and innovators.
More info >> |
|
|
